Skip to main content
Premium Trial:

Request an Annual Quote

Power3 to Begin Clinical Evaluation of Proteomics-Based Breast Cancer Test

NEW YORK, July 8 (GenomeWeb News) - Power3 Medical Products announced today that clinical evaluation of its proteomics-based early-detection breast cancer test will commence sometime this summer.


According to an outside spokesperson for Power3, the company will begin clinical testing at three undisclosed US sites, and that it would likely be able to announce the exact timing of the trials in a few weeks.


The test uses proteomics techniques such as electrophoresis image analysis and automated mass spectrometry to analyze nipple aspirate, or breast ductal fluid for specific groups of breast cancer proteins. The fluid is collected via a non-invasive modified breast pump procedure.


Power3 said that the test has the potential to detect breast cancer years earlier than current methods. The company also said it has completed proof-of-concept studies and secured the intellectual property for the test.


In May, Power3 acquired proteomics start-up ProteEx, which had been developing the test in collaboration with the M.D. Anderson Cancer Center.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.